Lymphoma vaccine therapy: next steps after a positive, controlled phase III clinical trial.

@article{Thomas2012LymphomaVT,
  title={Lymphoma vaccine therapy: next steps after a positive, controlled phase III clinical trial.},
  author={Sheeba K. Thomas and Larry W. Kwak},
  journal={Seminars in oncology},
  year={2012},
  volume={39 3},
  pages={
          253-62
        }
}
Many of the efforts toward developing vaccines against human malignancies have been frustrated by the lack of identification of a tumor-specific antigen that would allow tumor cells to be distinguished from normal cells. Idiotypic determinants of the surface immunoglobulin (Ig) associated with a given patient's B-cell lymphoma are unique to that tumor, and can thus serve as a tumor-specific marker. When conjugated to the immune carrier keyhole limpet hemocyanin (KLH), vaccination with an… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS